Industry and Geographic Information

The Company operates in one reportable segment. Sales to customers outside the U.S. represented 14%, 13% and 13% of total revenue for the years ended December 31, 2015, 2014 and 2013, respectively. As of December 31, 2015 and 2014, balances due from foreign customers, in U.S. dollars, were $5.6 million and $5.5 million, respectively.

The Company had sales to individual customers in excess of 10% of total revenue, as follows:



	Year ended December 31,
	2015		2014		2013
Customer:
A	20	%	19	%	19	%
B	17	%	18	%	16	%
C	11	%	11	%	8	%
	48	%	48	%	43	%

As of December 31, 2015 and 2014, accounts receivable from individual customers with balances due in excess of 10% of total accounts receivable totaled $12.0 million and $23.7 million, respectively.

The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands):



	Long-lived assets as of December 31,				Total revenue year ended December 31,
	2015		2014		2015		2014		2013
Domestic	$	52,426	$	49,052	$	168,809	$	159,845	$	154,626
Foreign	121		174		27,320		24,313		22,699
	$	52,547	$	49,226	$	196,129	$	184,158	$	177,325

Consolidated net product revenues by disease state are as follows (in thousands):



	Year ended December 31,
	2015		2014		2013
Infectious disease	$	141,857	$	130,416	$	128,079
Women’s health	37,161		34,332		33,328
Gastrointestinal disease	7,224		7,414		6,622
Royalty, license fees and grant revenue	6,189		7,681		3,917
Other	3,698		4,315		5,379
	$	196,129	$	184,158	$	177,325